<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-31051" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Velocardiofacial Syndrome</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Bishop</surname>
            <given-names>Bradie N.</given-names>
          </name>
          <aff>Brooke Army Medical Center</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Ward</surname>
            <given-names>Rebecca</given-names>
          </name>
          <aff>University of Florida</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Brady</surname>
            <given-names>Robert</given-names>
          </name>
          <aff>Uniformed Services University</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Bradie Bishop declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Rebecca Ward declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Robert Brady declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>17</day>
          <month>7</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-31051.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Velocardiofacial syndrome, also known as Di George syndrome or chromosome 22q11.2 syndrome, is the most common microdeletion syndrome in humans. Though there are a variety of presentations and phenotypes of velocardiofacial syndrome, a long, narrow face with a tubular nose, thin palpebral fissures, and a small mouth are present in more than 90 percent of cases. The four features that are most commonly observed are developmental delay, cardiac anomalies, palatal anomalies, and immune deficiency. Symptoms and phenotypes can range from minimal to severe and life-threatening. This activity describes the risk factors, evaluation, and management of velocardiofacial syndrome and highlights the role of the interprofessional team in enhancing care delivery for affected patients.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Describe the pathophysiology of velocardiofacial syndrome.</p></list-item><list-item><p>Explain when the diagnosis of velocardiofacial syndrome should be considered.</p></list-item><list-item><p>Describe the appropriate management of velocardiofacial syndrome.</p></list-item><list-item><p>Explain the importance of improving care coordination, with particular emphasis on communication between interprofessional medical teams, to enhance prompt and thorough delivery of care to patients with velocardiofacial syndrome.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=31051&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=31051">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-31051.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Initially described in the 1960s by Dr. Angelo Di George <xref ref-type="bibr" rid="article-31051.r1">[1]</xref>, velocardial facial syndrome (otherwise known as Di George syndrome or Chromosome 22q11.2 syndrome) is the most common microdeletion syndrome in humans.&#x000a0;<xref ref-type="bibr" rid="article-31051.r2">[2]</xref><xref ref-type="bibr" rid="article-31051.r3">[3]</xref>&#x000a0;A 3 Mb deletion of LCR22A-D is the most common deletion present, though other deletions can be seen with varying phenotypes. <xref ref-type="bibr" rid="article-31051.r3">[3]</xref> Though there are a variety of presentations and phenotypes possible in&#x000a0;velocardial facial syndrome, common presenting features include immune deficiency, recurrent infections, hypocalcemia, seizures, CNS anomalies, psychiatric problems, short stature, macro- or microcephaly, intellectual delays, congenital heart disease genitourinary anomalies, and palatal anomalies. <xref ref-type="bibr" rid="article-31051.r3">[3]</xref>&#x000a0;Symptoms and phenotypes can range from only a few features to severe and life-threatening. A long, narrow face with a tubular nose, thin palpebral fissures, and a small mouth are present in greater than 90% of cases. <xref ref-type="bibr" rid="article-31051.r4">[4]</xref></p>
      </sec>
      <sec id="article-31051.s3" sec-type="Etiology">
        <title>Etiology</title>
        <p>Velocardial facial syndrome is the result of a microdeletion of DNA on a single copy of chromosome 22q11.2. <xref ref-type="bibr" rid="article-31051.r5">[5]</xref> Most deletions&#x000a0;occur spontaneously. However, as patients with velocardial facial syndrome survive into adulthood, their potential offspring have a 50% chance of inheriting the syndrome. <xref ref-type="bibr" rid="article-31051.r3">[3]</xref>&#x000a0;A variety of breakpoints can occur, with variability in phenotypes secondary to where and what DNA is lost. Deletions are categorized as proximal, central, and distal.&#x000a0;<xref ref-type="bibr" rid="article-31051.r3">[3]</xref></p>
        <p>The actual break in the chromosome occurs during an unequal meiotic exchange. An area of the chromosome&#x000a0;with low copy number repeats is particularly susceptible&#x000a0;to loss during meiosis.&#x000a0;<xref ref-type="bibr" rid="article-31051.r6">[6]</xref>&#x000a0;Approximately 30 to 40 genes can be lost. Most patients with velocardial facial syndrome have 3 million base pairs deleted.&#x000a0;</p>
        <p>Without the 22q11.2 region, abnormal neural crest migration occurs, resulting in the 3rd and 4th pharyngeal pouches improperly migrating.&#x000a0;Subsequent thymic hypoplasia, parathyroid hypoplasia, and conotruncal cardiac anomalies occur and lead to immunodeficiency and hypocalcemia. A gene known as&#x000a0;T-box transcription factor (TBX1) is thought to be responsible for some of the abnormal neural crest migration.&#x000a0;<xref ref-type="bibr" rid="article-31051.r7">[7]</xref></p>
      </sec>
      <sec id="article-31051.s4" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>Most patients with velocardial facial syndrome arise from a de novo microdeletion, with subsequent autosomal dominant inheritance. Prevalence ranges from 1 to 2 per 4,000 live births, with an increased incidence in patients with cardiovascular malformations.&#x000a0;<xref ref-type="bibr" rid="article-31051.r3">[3]</xref><xref ref-type="bibr" rid="article-31051.r8">[8]</xref><xref ref-type="bibr" rid="article-31051.r7">[7]</xref>&#x000a0;There is no male or female predominance. <xref ref-type="bibr" rid="article-31051.r9">[9]</xref></p>
        <p>There does not appear to be an association with any ethnic group and the development of velocardial facial syndrome. <xref ref-type="bibr" rid="article-31051.r7">[7]</xref></p>
        <p>Though patients with velocardial facial syndrome generally have unaffected fertility, their offspring have a 50% chance of inheriting the syndrome. <xref ref-type="bibr" rid="article-31051.r5">[5]</xref></p>
      </sec>
      <sec id="article-31051.s5" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>Velocardial facial syndrome has a wide range of findings due to both differences in the amount of genetic material lost and environmental factors. The most&#x000a0;common results are&#x000a0;developmental delays, cardiac anomalies, palatal anomalies, and immune deficiency. <xref ref-type="bibr" rid="article-31051.r6">[6]</xref><xref ref-type="bibr" rid="article-31051.r9">[9]</xref></p>
      </sec>
      <sec id="article-31051.s6" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>Major birth defects like conotruncal cardiac anomalies, thymic hypoplasia, or velopharyngeal insufficiency should prompt consideration of velocardial facial syndrome in a newborn infant, particularly if the patient also has hypocalcemia. <xref ref-type="bibr" rid="article-31051.r5">[5]</xref> Other patients may be picked up&#x000a0;when a newborn is screened for severe combined immunodeficiency. <xref ref-type="bibr" rid="article-31051.r7">[7]</xref></p>
        <p>Psychiatric symptoms, such as difficulties in learning or attention deficit disorder, may be the presenting complaints of patients with velocardial facial syndrome, particularly in older adolescents and adults. <xref ref-type="bibr" rid="article-31051.r5">[5]</xref> Up to a quarter of patients will develop schizophrenia or schizoaffective disorder.<xref ref-type="bibr" rid="article-31051.r5">[5]</xref></p>
        <p>The four features most commonly are developmental delays, cardiac anomalies, palatal anomalies, and immune deficiency. <xref ref-type="bibr" rid="article-31051.r6">[6]</xref>
<xref ref-type="bibr" rid="article-31051.r9">[9]</xref></p>
        <p>Features of a velocardial facial syndrome:&#x000a0;<xref ref-type="bibr" rid="article-31051.r5">[5]</xref><xref ref-type="bibr" rid="article-31051.r6">[6]</xref></p>
        <list list-type="bullet">
          <list-item>
            <p>Dysmorphic facial features: long, narrow face, tubular nose with a bulbous tip, narrow palpebral fissures, small mouth, and ears</p>
          </list-item>
          <list-item>
            <p>Development and learning disabilities, particularly in math</p>
          </list-item>
          <list-item>
            <p>Hypernasal speech</p>
          </list-item>
          <list-item>
            <p>Hypocalcemia and hypoparathyroidism</p>
          </list-item>
          <list-item>
            <p>Hypo- or hyperthyroidism</p>
          </list-item>
          <list-item>
            <p>Psychiatric disorders, including schizophrenia, depression, autism spectrum, attention deficit, obsessive-compulsive</p>
          </list-item>
          <list-item>
            <p>Recurrent seizures</p>
          </list-item>
          <list-item>
            <p>Cardiovascular malformations</p>
          </list-item>
          <list-item>
            <p>Scoliosis</p>
          </list-item>
          <list-item>
            <p>Renal and urogenital anomalies</p>
          </list-item>
          <list-item>
            <p>Strabismus</p>
          </list-item>
          <list-item>
            <p>Recurrent infections</p>
          </list-item>
          <list-item>
            <p>Obesity</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-31051.s7" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>Multiplex ligation-dependent probe amplification (MLPA) and single nucleotide polymorphism (SNP) arrays are the preferred methods to detect microdeletions of chromosome 22q11, but fluorescence in-situ hybridization can be used as well.&#x000a0;<xref ref-type="bibr" rid="article-31051.r7">[7]</xref>&#x000a0;Pre-natal ultrasonography can detect clinical features, such as an interrupted aortic arch, that should prompt consideration of velocardial facial syndrome. <xref ref-type="bibr" rid="article-31051.r6">[6]</xref> In particular, one study recommended that finding polyhydramnios in conjunction with another low-risk anomaly should prompt genetic testing. <xref ref-type="bibr" rid="article-31051.r6">[6]</xref></p>
        <p>Hypocalcemia is a common finding and requires close monitoring. <xref ref-type="bibr" rid="article-31051.r5">[5]</xref></p>
        <p>Thrombocytopenia with increased platelet size can be seen in patients with velocardial facial syndrome when the GPIBB gene is deleted, resulting in decreased expression of GPIb-IX-V on the platelet surface. <xref ref-type="bibr" rid="article-31051.r10">[10]</xref>
<xref ref-type="bibr" rid="article-31051.r6">[6]</xref> An increased propensity for bleeding and epistaxis is frequently seen in patients with this deletion. <xref ref-type="bibr" rid="article-31051.r10">[10]</xref></p>
        <p>As patients age, hypothyroidism and hypoparathyroidism often develop. <xref ref-type="bibr" rid="article-31051.r5">[5]</xref></p>
      </sec>
      <sec id="article-31051.s8" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>Four features commonly seen in patients with velocardial facial syndrome that significantly impact the quality of life and require medical management are developmental delays, cardiac anomalies, palatal anomalies, and immune deficiency. <xref ref-type="bibr" rid="article-31051.r6">[6]</xref> Patients should be seen with a multi-disciplinary team based on their particular phenotype and their age.</p>
        <p>The cardiac anomalies most commonly seen&#x000a0;with velocardial facial syndrome are tetralogy of Fallot, pulmonary atresia, truncus arteriosus, interrupted aortic arch, and ventricular septal defect. Early intervention by an experienced pediatric cardiothoracic surgeon is ideal for possible repair and or monitoring. Cardiac abnormalities have the most significant impact on morbidity and mortality. <xref ref-type="bibr" rid="article-31051.r6">[6]</xref></p>
        <p>Palatal defects can cause difficulties in feeding due to muscle weakness in the nasopharyngeal area. <xref ref-type="bibr" rid="article-31051.r6">[6]</xref>&#x000a0;Nasogastric or gastrostomy feeding tubes may be necessary to aid in feeding; however, many feeding difficulties can be managed with thickeners and anti-reflux medications. <xref ref-type="bibr" rid="article-31051.r6">[6]</xref>&#x000a0;Breastfeeding may be extremely challenging due to muscle weakness and cleft palate. Discussing options and expectations with new parents should be considered a critical part of the care plan.</p>
        <p>Patients with hypocalcemia should be supplemented with calcium and vitamin D, and their levels monitored. Hypercalcemia can be very damaging and should be avoided.<xref ref-type="bibr" rid="article-31051.r6">[6]</xref></p>
        <p>As a patient with velocardial facial syndrome ages, his medical needs will change, and things like early education of parents are key. Additionally, growth should be evaluated using specialized growth charts. <xref ref-type="bibr" rid="article-31051.r9">[9]</xref></p>
      </sec>
      <sec id="article-31051.s9" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <p>Thymic aplasia and congenital hypoparathyroidism can be seen in&#x000a0;<xref ref-type="bibr" rid="article-31051.r7">[7]</xref></p>
        <list list-type="bullet">
          <list-item>
            <p>CHARGE syndrome</p>
          </list-item>
          <list-item>
            <p>Chromosome anomalies on 4q21.3, 10p13-14, 11q23-ter</p>
          </list-item>
          <list-item>
            <p>Maternal diabetes or retinoic acid exposure</p>
          </list-item>
        </list>
        <p>Other syndromes that may be considered include Smith-Lemli-Opitz syndrome, Kabuki syndrome, and Goldenhar syndrome. <xref ref-type="bibr" rid="article-31051.r6">[6]</xref></p>
        <p>Due to the subtle and varied phenotype of velocardial facial syndrome, it is important to keep it on the differential&#x000a0;diagnosis in any patient with congenital anomalies, learning difficulties, and immune deficiencies.</p>
      </sec>
      <sec id="article-31051.s10" sec-type="Prognosis">
        <title>Prognosis</title>
        <p>Complications of congenital cardiac anomalies can result in childhood death (less than 4%), but with increasing knowledge of how to repair these anomalies, many patients are living into adulthood. There has been no defined life expectancy for these patients. <xref ref-type="bibr" rid="article-31051.r6">[6]</xref></p>
      </sec>
      <sec id="article-31051.s11" sec-type="Complications">
        <title>Complications</title>
        <p>Cardiac anomalies are commonly seen in velocardial facial syndrome and frequently need repair. Complications from surgery, particularly in the newborn stage, may occur and should be explored with parents before surgery.</p>
        <p>Autoimmune disease is seen in approximately 10% of patients with velocardial facial syndrome, most likely secondary to their immune deficiency from thymic hypoplasia. <xref ref-type="bibr" rid="article-31051.r6">[6]</xref>&#x000a0;Additionally, these patients appear to have an increased incidence of allergies as well.&#x000a0;<xref ref-type="bibr" rid="article-31051.r6">[6]</xref></p>
        <p>Idiopathic thrombocytopenia (ITP) and autoimmune hemolytic anemia (AIHA) occur with increased frequency in patients with velocardial facial syndrome.&#x000a0;<xref ref-type="bibr" rid="article-31051.r10">[10]</xref></p>
        <p>Velocardial facial syndrome patients are at increased risk for hematologic malignancies due to a depressed immune system. <xref ref-type="bibr" rid="article-31051.r10">[10]</xref>&#x000a0;Recent studies have demonstrated an association of atypical teratoid/rhabdoid tumors with the SMARCB1 variant with velocardial facial syndrome.</p>
        <p>Depending on the severity of immunodeficiency, patients with velocardial facial syndrome may be at higher risk for viral infections, particularly in childhood. These infections may last longer and have more frequent bacterial infections superimposed. Close monitoring and early treatment are required.</p>
      </sec>
      <sec id="article-31051.s12" sec-type="Deterrence and Patient Education">
        <title>Deterrence and Patient Education</title>
        <p>Learning disabilities are a common feature of velocardial facial syndrome, and children may benefit from early intervention. Parents should be educated about milestones to look for and warning signs to help their child seek intervention as soon as possible.&#x000a0;</p>
        <p>Moving into adolescence and adulthood, the signs and symptoms of schizophrenia, depression, and attention deficit disorder, among other psychiatric&#x000a0;illnesses, should be discussed as they are common findings associated with velocardial facial syndrome.</p>
        <p>No environmental&#x000a0;or age-related&#x000a0;factors have been implicated in the deletion of chromosome&#x000a0;22q11.</p>
      </sec>
      <sec id="article-31051.s13" sec-type="Pearls and Other Issues">
        <title>Pearls and Other Issues</title>
        <p>Catch-22 is a common mnemonic used to remember the most common phenotypes in patients with myocardial facial syndrome. The 22 refers to the chromosome.</p>
        <list list-type="bullet">
          <list-item>
            <p>C - cardiac anomalies</p>
          </list-item>
          <list-item>
            <p>A - abnormal facies</p>
          </list-item>
          <list-item>
            <p>T - thymic hypoplasia</p>
          </list-item>
          <list-item>
            <p>C - Cellular immune deficiency</p>
          </list-item>
          <list-item>
            <p>H - hypoparathyroidism and hypocalcemia</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-31051.s14" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Velocardial facial syndrome requires an interprofessional team approach to take care of the patient. The syndrome has features that span many fields, including medical genetics, pediatrics, psychiatry, endocrinology, speech pathology, neurology, orthopedics, ophthalmology, family medicine, cardiovascular surgery, gastroenterology, and immunology.</p>
        <p>The expectations for each stage of development should be discussed early on with parents, with a particular emphasis&#x000a0;on their specific child's phenotype. Even within families, the presenting symptoms can range wildly, so care should ideally be tailored to the individual patient.</p>
      </sec>
      <sec id="article-31051.s15">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=31051&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=31051">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/genetic-disorders/velocardiofacial-syndrome/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=31051">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/31051/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=31051">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-31051.s16">
        <title>References</title>
        <ref id="article-31051.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Di George</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Lischner</surname>
                <given-names>HW</given-names>
              </name>
              <name>
                <surname>Dacou</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Arey</surname>
                <given-names>JB</given-names>
              </name>
            </person-group>
            <article-title>Absence of the thymus.</article-title>
            <source>Lancet</source>
            <year>1967</year>
            <month>Jun</month>
            <day>24</day>
            <volume>1</volume>
            <issue>7504</issue>
            <fpage>1387</fpage>
            <pub-id pub-id-type="pmid">4165192</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31051.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sullivan</surname>
                <given-names>KE</given-names>
              </name>
            </person-group>
            <article-title>Chromosome 22q11.2 deletion syndrome and DiGeorge syndrome.</article-title>
            <source>Immunol Rev</source>
            <year>2019</year>
            <month>Jan</month>
            <volume>287</volume>
            <issue>1</issue>
            <fpage>186</fpage>
            <page-range>186-201</page-range>
            <pub-id pub-id-type="pmid">30565249</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31051.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Burnside</surname>
                <given-names>RD</given-names>
              </name>
            </person-group>
            <article-title>22q11.21 Deletion Syndromes: A Review of Proximal, Central, and Distal Deletions and Their Associated Features.</article-title>
            <source>Cytogenet Genome Res</source>
            <year>2015</year>
            <volume>146</volume>
            <issue>2</issue>
            <fpage>89</fpage>
            <page-range>89-99</page-range>
            <pub-id pub-id-type="pmid">26278718</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31051.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Adams</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Clark</surname>
                <given-names>DA</given-names>
              </name>
            </person-group>
            <article-title>Common genetic and epigenetic syndromes.</article-title>
            <source>Pediatr Clin North Am</source>
            <year>2015</year>
            <month>Apr</month>
            <volume>62</volume>
            <issue>2</issue>
            <fpage>411</fpage>
            <page-range>411-26</page-range>
            <pub-id pub-id-type="pmid">25836705</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31051.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kapadia</surname>
                <given-names>RK</given-names>
              </name>
              <name>
                <surname>Bassett</surname>
                <given-names>AS</given-names>
              </name>
            </person-group>
            <article-title>Recognizing a common genetic syndrome: 22q11.2 deletion syndrome.</article-title>
            <source>CMAJ</source>
            <year>2008</year>
            <month>Feb</month>
            <day>12</day>
            <volume>178</volume>
            <issue>4</issue>
            <fpage>391</fpage>
            <page-range>391-3</page-range>
            <pub-id pub-id-type="pmid">18268261</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31051.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>McDonald-McGinn</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Sullivan</surname>
                <given-names>KE</given-names>
              </name>
            </person-group>
            <article-title>Chromosome 22q11.2 deletion syndrome (DiGeorge syndrome/velocardiofacial syndrome).</article-title>
            <source>Medicine (Baltimore)</source>
            <year>2011</year>
            <month>Jan</month>
            <volume>90</volume>
            <issue>1</issue>
            <fpage>1</fpage>
            <page-range>1-18</page-range>
            <pub-id pub-id-type="pmid">21200182</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31051.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Swillen</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>McDonald-McGinn</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Developmental trajectories in 22q11.2 deletion.</article-title>
            <source>Am J Med Genet C Semin Med Genet</source>
            <year>2015</year>
            <month>Jun</month>
            <volume>169</volume>
            <issue>2</issue>
            <fpage>172</fpage>
            <page-range>172-81</page-range>
            <pub-id pub-id-type="pmid">25989227</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31051.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Panamonta</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Wichajarn</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Chaikitpinyo</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Panamonta</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Pradubwong</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Chowchuen</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>Birth Prevalence of Chromosome 22q11.2 Deletion Syndrome: A Systematic Review of Population-Based Studies.</article-title>
            <source>J Med Assoc Thai</source>
            <year>2016</year>
            <month>Aug</month>
            <volume>99 Suppl 5</volume>
            <fpage>S187</fpage>
            <page-range>S187-93</page-range>
            <pub-id pub-id-type="pmid">29906080</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31051.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hac&#x00131;hamdio&#x0011f;lu</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Hac&#x00131;hamdio&#x0011f;lu</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Delil</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>22q11 deletion syndrome: current perspective.</article-title>
            <source>Appl Clin Genet</source>
            <year>2015</year>
            <volume>8</volume>
            <fpage>123</fpage>
            <page-range>123-32</page-range>
            <pub-id pub-id-type="pmid">26056486</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31051.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lambert</surname>
                <given-names>MP</given-names>
              </name>
              <name>
                <surname>Arulselvan</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Schott</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Markham</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Crowley</surname>
                <given-names>TB</given-names>
              </name>
              <name>
                <surname>Zackai</surname>
                <given-names>EH</given-names>
              </name>
              <name>
                <surname>McDonald-McGinn</surname>
                <given-names>DM</given-names>
              </name>
            </person-group>
            <article-title>The 22q11.2 deletion syndrome: Cancer predisposition, platelet abnormalities and cytopenias.</article-title>
            <source>Am J Med Genet A</source>
            <year>2018</year>
            <month>Oct</month>
            <volume>176</volume>
            <issue>10</issue>
            <fpage>2121</fpage>
            <page-range>2121-2127</page-range>
            <pub-id pub-id-type="pmid">28940864</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
